Effects of human relaxin-2 (serelaxin) on hypoxic pulmonary vasoconstriction during acute hypoxia in a sheep model.

PURPOSE

Hypoxia induces pulmonary vasoconstriction with a subsequent increase of pulmonary artery pressure (PAP), which can result in pulmonary hypertension. Serelaxin has shown an increase of pulmonary hemodynamic parameters after serelaxin injection. We therefore investigated the response of pulmonary hemodynamic parameters after serelaxin administration in a clinically relevant model.

METHODS

Six controls and six sheep that received 30 μg/kg serelaxin underwent right heart catheterization during a 12-minute hypoxia period (inhalation of 5% oxygen and 95% nitrogen) and subsequent reoxygenation. Systolic, diastolic, and mean values of both PAP (respectively, PAPs, PAPd, and PAPm) and pulmonary capillary wedge pressure (respectively, PCWPs, PCWPd, and PCWPm), blood gases, heart rate (HR), and both peripheral and pulmonary arterial oxygen saturation were obtained. Cardiac output (CO), stroke volume (SV), pulmonary vascular resistance (PVR), pulmonary arterial compliance (PAcompl), and systemic vascular resistance (SVR) were calculated.

RESULTS

The key findings of the current study are that serelaxin prevents the rise of PAPs (≤0.001), PAPm, PCWPm, PCWPs (≤0.03), and PAPd (≤0.05) during hypoxia, while it simultaneously increases CO and SV (≤0.001). Similar courses of decreases of PAPm, PAPd, PAPs, CO, SVR (≤0.001), and PCWPd (≤0.03) as compared to hypoxic values were observed during reoxygenation. In direct comparison, the experimental groups differed during hypoxia in regard to HR, PAPm, PVR, and SVR (≤0.03), and during reoxygenation in regard to HR (≤0.001), PAPm, PAPs, PAPd, PVR, SVR (≤0.03), and PCWPd (≤0.05).

CONCLUSION

The findings of this study suggest that serelaxin treatment improves pulmonary hemodynamic parameters during acute hypoxia.